Ibritumomab Intravenous and Lorcaserin Extended-Release Tablets
Determining the interaction of Ibritumomab Intravenous and Lorcaserin Extended-Release Tablets and the possibility of their joint administration.
No interaction was detected between the selected drugs or effects of joint drug administration are currently understudied, and it takes time and accumulated statistics to determine their interaction. A doctor should be consulted to address the issue of joint drug administration.
Generic Name: ibritumomab
Brand name: Y-90 Zevalin, In-111 Zevalin
Synonyms: Ibritumomab, Ibritumomab Tiuxetan
Generic Name: lorcaserin
Brand name: Belviq, Belviq XR
Synonyms: Lorcaserin
In the course of checking the drug compatibility and interactions, data from the following reference sources was used: Drugs.com, Rxlist.com, Webmd.com, Medscape.com.
- Ibritumomab Intravenous-Lorcaserin Hydrochloride
- Ibritumomab Intravenous-Lorcaserin Tablets
- Ibritumomab Intravenous-Lorcet
- Ibritumomab Intravenous-Lorcet Plus
- Ibritumomab Intravenous-Lorcet Tablets
- Ibritumomab Intravenous-Lorlatinib
- Lorcaserin Extended-Release Tablets-Ibritumomab Tiuxetan
- Lorcaserin Extended-Release Tablets-Ibrutinib
- Lorcaserin Extended-Release Tablets-Ibrutinib Capsules
- Lorcaserin Extended-Release Tablets-Ibrutinib Tablets
- Lorcaserin Extended-Release Tablets-Ibu
- Lorcaserin Extended-Release Tablets-IBU Tablets